Key Summary
- MHRA shared safety warnings for all botulinum toxin type A products.
- This follows reports of rare cases of botulism linked to their use.
- Patients are advised to seek immediate medical attention if they experience symptoms after treatment.
The Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened warnings for botulinum toxin type A products following small numbers of botulism cases associated with their use.
In rare cases, the toxin’s action can extend beyond the intended local area and produce systemic symptoms.
The MHRA has worked with manufacturers to revise product literature and patient leaflets to better explain the risk of iatrogenic botulism – that is, botulism resulting from medical treatment.
Patients are advised to seek immediate medical attention if they experience symptoms after treatment, including difficulty swallowing, slurred speech, breathing difficulties, or muscle weakness. These symptoms can occur within days or up to four weeks after treatment.
Dr Alison Cave, the MHRA’s Chief Safety Officer, said that although botulinum toxin treatments are effective when used correctly, the strengthened warnings are important reminders of rare but serious risks.
She urged clinicians and patients to recognise botulism signs and to act quickly, and she cautioned the public to avoid unlicensed products and to seek care only from properly qualified professionals. The MHRA continues to monitor safety data and emerging evidence.
Dr Martin Bewley of UK Health Security Agency added that botulism, while uncommon, can be severe.
He encouraged anyone with recent treatment who develops worrying symptoms – particularly swallowing difficulties – to contact NHS 111 (or the local equivalent) and to obtain immediate medical attention if necessary. He reiterated the importance of using licensed practitioners and authorised products.
The MHRA noted some factors that can increase the chance of adverse reactions, including underlying neurological conditions, a prior history of dysphagia or aspiration, the use of high doses, and injecting products outside their licensed indications or into unapproved sites.
Regulators also highlighted the risks posed by unregulated or counterfeit products obtained outside legitimate supply chains; such items may not meet UK safety or quality standards and can raise the likelihood of serious harm.
The MHRA’s Criminal Enforcement Unit has opened several investigations into the use of unlicensed botulinum toxin products after a rise in related hospital admissions last year.
Anyone considering treatment is advised to confirm their practitioner’s qualifications and make sure the product used is authorised for use in the UK.
